<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774406</url>
  </required_header>
  <id_info>
    <org_study_id>Pharmaco 20200224</org_study_id>
    <nct_id>NCT04774406</nct_id>
  </id_info>
  <brief_title>Pulmonary Toxicities Related to PARP Inhibitors (PulmonaRIB)</brief_title>
  <official_title>Pulmonary Toxicities With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (PulmonaRIB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients&#xD;
      receiving PARPi may experience rare but serious (or not) adverse events such as pulmonary&#xD;
      toxicities whose data are scarce.&#xD;
&#xD;
      The objective was to investigate reports of pulmonary toxicities related to PARPi, including&#xD;
      olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the World Health&#xD;
      Organization's (WHO) pharmacovigilance database: VigiBase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Here, investigators use the World Health Organization's (WHO) database of individual safety&#xD;
      case reports, to identify cases of pulmonary toxicities related to PARPi.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary toxicities reports related to PARPi.</measure>
    <time_frame>From inception to March, 2021</time_frame>
    <description>Identification of the pulmonary toxicities adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the latency period since first PARPi exposure</measure>
    <time_frame>From inception to March, 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of patients who experienced co-reported adverse events</measure>
    <time_frame>From inception to March, 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the fatality rate</measure>
    <time_frame>From inception to March, 2021</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>parp inhibitors</arm_group_label>
    <description>All patients treated at least with 1 PARPi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib</intervention_name>
    <description>All patients treated at least with 1 PARPi (alone or in combination)</description>
    <arm_group_label>parp inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients treated with PARPi and experiencing pulmonary toxicities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  case reported in the World Health Organization (WHO) database (VigiBase) of individual&#xD;
             safety case reports at the time of the extraction,&#xD;
&#xD;
          -  patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC&#xD;
             L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60),&#xD;
             veliparib (none) and pamiparib (none).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -chronology not compatible between the PARPi and adverse event&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Joachim Alexandre, MD</last_name>
    <phone>0231064670</phone>
    <email>alexandre-j@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandre Joachim</name>
      <address>
        <city>Caen</city>
        <state>Basse Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Alexandre, MD</last_name>
      <phone>+33231064670</phone>
      <email>alexandre-j@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Niraparib</mesh_term>
    <mesh_term>Veliparib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

